Drug record
What four public record sets show for insulin glargine. Saved Nov 10, 2026.
| Shortage | Not on the FDA shortage list | Details |
|---|---|---|
| Pharmacy cost | Brand prices only, see table | Details |
| Medicare Part D, 2024 | $2.73 billion | Details |
| FDA recall records | 3 | Details |
Whether the FDA lists this drug as in short supply.
1 product being discontinued. A maker has told the FDA it will stop making these. That is one maker leaving, not a shortage of the drug:
The list changes daily, and it covers the national supply. A pharmacy near you can be out of a drug that is not listed, or have one that is. See today's status.
The national average price retail pharmacies pay to buy it (NADAC).
| Product as surveyed | Type | Pharmacy pays | For 30 | Price since |
|---|---|---|---|---|
| INSULIN GLARGINE MAX SOLO U300 | Generic | $26.96 per mL | — | Oct 21, 2026 |
| INSULIN GLARGINE SOLOSTAR U300 | Generic | $26.99 per mL | — | Oct 21, 2026 |
| INSULIN GLARGINE-YFGN U100 PEN | Generic | $2.90 per mL | — | Oct 21, 2026 |
| INSULIN GLARGINE-YFGN U100 VL | Generic | $6.09 per mL | — | Oct 21, 2026 |
| BASAGLAR 100 UNIT/ML KWIKPEN | Brand | $20.92 per mL | — | Oct 21, 2026 |
| LANTUS 100 UNIT/ML VIAL | Brand | $6.15 per mL | — | Oct 21, 2026 |
| LANTUS SOLOSTAR 100 UNIT/ML | Brand | $6.16 per mL | — | Oct 21, 2026 |
| REZVOGLAR 100 UNIT/ML KWIKPEN | Brand | $5.92 per mL | — | Oct 21, 2026 |
| SEMGLEE (YFGN) 100 UNIT/ML PEN | Brand | $25.74 per mL | — | Oct 21, 2026 |
| SEMGLEE (YFGN) 100 UNIT/ML VL | Brand | $26.07 per mL | — | Sep 23, 2026 |
| TOUJEO MAX SOLOSTR 300 UNIT/ML | Brand | $91.28 per mL | — | Oct 21, 2026 |
| TOUJEO SOLOSTAR 300 UNIT/ML | Brand | $91.28 per mL | — | Oct 21, 2026 |
This is not your price. NADAC is the national average that retail pharmacies pay to buy the drug, from the Medicaid survey for the week of Nov 11, 2026. What you pay adds the pharmacy's markup and dispensing fee and depends on your insurance or any discount card. "For 30" is shown only for products priced per tablet or capsule. Brand prices here are before any rebates.
Medicare Part D spending by product, from the latest annual file (2024).
In 2024, Medicare Part D plans and their members paid $2.73 billion for the 13 products below. That is down 47% from $5.18 billion in 2020.
| Product | 2024 spending | People | Per prescription | Per person, year | 2020 spending |
|---|---|---|---|---|---|
| Lantus Solostar Insulin Glargine,Hum.Rec.Anlog | $699.1 million | 1,415,422 | $125.50 | $493.94 | $2.66 billion |
| Basaglar Kwikpen U-100 Insulin Glargine,Hum.Rec.Anlog | $664.6 million | 422,745 | $373.88 | $1,572.18 | $689.3 million |
| Toujeo Max Solostar Insulin Glargine,Hum.Rec.Anlog | $561.2 million | 134,394 | $1,091.57 | $4,175.68 | $205.9 million |
| Toujeo Solostar Insulin Glargine,Hum.Rec.Anlog | $550.0 million | 189,494 | $720.84 | $2,902.33 | $570.0 million |
| Lantus Insulin Glargine,Hum.Rec.Anlog | $139.9 million | 271,761 | $125.26 | $514.77 | $1.06 billion |
| Semglee (Yfgn) Pen Insulin Glargine-Yfgn | $58.6 million | 51,446 | $436.26 | $1,138.27 | — |
| Insulin Glargine-Yfgn Insulin Glargine-Yfgn | $36.3 million | 171,950 | $83.03 | $211.32 | — |
| Semglee (Yfgn) Insulin Glargine-Yfgn | $6.7 million | 5,264 | $462.53 | $1,278.64 | — |
| Insulin Glargine Solostar Insulin Glargine,Hum.Rec.Anlog | $5.3 million | 23,129 | $155.97 | $230.61 | — |
| Insulin Glargine Insulin Glargine,Hum.Rec.Anlog | $2.7 million | 10,711 | $148.90 | $252.40 | — |
| Insulin Glargine Max Solostar Insulin Glargine,Hum.Rec.Anlog | $1.7 million | 3,366 | $295.52 | $498.41 | — |
| Rezvoglar Kwikpen Insulin Glargine-Aglr | $585,935 | 2,344 | $89.40 | $249.97 | — |
| Basaglar Tempo Pen U-100 Insulin Glargine,Hum.Rec.Anlog | $580,890 | 1,054 | $316.56 | $551.13 | — |
Spending is the gross amount paid at the pharmacy by Part D plans and patients, before manufacturer rebates, which can be large for brand drugs. The same person can use more than one product, so people are not added up across rows. A dash means the file suppresses a small number or has no figure for that year. Not counted here, combination products that contain it: Soliqua 100-33.
Recalls reported to the FDA that name this drug.
The FDA has 3 recall records that name insulin glargine in the product description (3 Class I).
Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens (NDC 49502-394-71), packaged in cartons of 5 prefilled pens (NDC 49502-394-75), Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 15317, Manufactured for: Mylan Specialty L.P., Morgantown, WV
Reason: Labeling: Missing label: Label missing from some prefilled pens.
Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), packaged in a 10 mL Multiple-Dose vial inside a carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Manufactured for: Mylan Specialty L.P., Morgantown, WV 26505, NDC 49502-393-80
Reason: Labeling: Missing label on the vial
Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens per carton (NDC 49502-0196-75), Rx only, Manufactured in Malaysia for: Mylan Specialty L.P., Morgantown, WV, 26505.
Reason: Labeling: Missing Label: label missing from some Semglee prefilled pens.
A recall covers specific lots from one company, not every bottle of the drug. Records include combination products and compounded versions that name this ingredient. Class I is the most serious: use could cause serious harm. Class II may cause temporary or reversible harm. Class III is unlikely to cause harm. To check a bottle, match the lot number on the label. See the live list. Do not stop a medicine because of a recall without asking your pharmacist.
These are saved records as of Nov 10, 2026; the sources update daily to yearly. For current figures open the live report for insulin glargine. This page is public-record information, not medical advice.